SNM reaction to OMB position on nuclear byproduct materials

September 19, 2001

Reston, Virginia....The American College of Nuclear Physicians (ACNP) and the Society of Nuclear Medicine (SNM) today told the Director of the Office of Management and Budget's Office of Information and Regulatory Affairs (OIRA) that it welcomed his expression of concern "that the benefits of regulating medical uses of byproduct materials may not justify the costs of the Part 35 requirements."

Nuclear byproduct materials are used to produce some of the tracer elements injected into patients to conduct many potentially life-saving nuclear medicine procedures such as cardiac stress tests to analyze heart function; lung scans to verify blood clots; bone scans to diagnose orthopedic injuries, and to determine if cancer has metastasized.

OIRA Director John D. Graham's comments were made in a letter to ACNP regarding the Nuclear Regulatory Commission's proposed revision of 10 C.F. R. Part 35, which governs the medical use of byproduct material. Because the NRC is an independent regulatory agency, OMB cannot require it to conduct a regulatory analysis of its rule. OMB did, however, require the NRC to evaluate its program to consider further reductions in the burden imposed by its requirements, and encouraged the NRC to undertake a full evaluation of the benefits and costs of the various requirements of Part 35, and to consider alternatives such as third-party accreditation and increased reliance on State regulations and professional standards.

ACNP and SNM, which expressed support for OMB's position, nonetheless noted that they believe even this type of analysis is largely unnecessary, since the National Academy of Sciences/Institute of Medicine has already concluded, in a report sponsored by the NRC itself, that:

"Compared to the regulatory systems in place for the other 90 percent of medical use of ionizing radiation, the more detailed reporting and enforcement systems required for byproduct materials [subject to NRC regulation] do not seem to result in even a marginal decrease in risk to providers, patients, or members of the public." National Academy of Sciences-Institute of Medicine, RADIATION IN MEDICINE - A NEED FOR REFORM at p. 171 (1996).

ACNP President-elect Gary L. Dillehay, M.D. also noted that "Despite repeated promises to us and to the Congress that it would do so, the NRC continues to impose an unnecessary and excessively expensive regulatory scheme on diagnostic nuclear medicine." Dillehay also noted that ACNP and SNM believe that proposed regulations by the NRC will have a seriously adverse affect on the production of nuclear byproduct materials.

"In the interests of our patients and the Nation's health care system, we will continue to work to assure that diagnostic nuclear medicine is subject to an appropriate regulatory scheme," he added.

In its letter to NRC OMB did approve the paperwork collection requirements of the proposed revision.

Approximately 13 million nuclear medicine procedures are performed on patients each year, and the average American receives 3.8 nuclear medicine procedures during his or her lifetime.
The Society of Nuclear Medicine is an international scientific and professional organization of more than 13,000 members dedicated to promoting the science, technology, and practical application of nuclear medicine. The American College of Nuclear Physicians represents the socio-economic interests of the nuclear medicine community. SNM and ACNP are based in Reston, Virginia. For more information, visit the SNM web site at or the ACNP web site at

Society of Nuclear Medicine

Related Nuclear Medicine Articles from Brightsurf:

Nuclear medicine and COVID-19: New content from The Journal of Nuclear Medicine
In one of five new COVID-19-related articles and commentaries published in the June issue of The Journal of Nuclear Medicine, Johnese Spisso discusses how the UCLA Hospital System has dealt with the pandemic.

Story tips: Shuffling atoms, thinning forests, fusion assembly and nuclear medicine
ORNL Story Tips: Shuffling atoms, thinning forests, fusion assembly and nuclear medicine.

Global nuclear medicine community shares COVID-19 strategies and experiences
In an effort to provide safer working environments for nuclear medicine professionals and their patients, clinics across five continents have shared their approaches to containing the spread of COVID-19 in a series of editorials, published ahead of print in The Journal of Nuclear Medicine.

Influence of the Journal of Nuclear Medicine jumps 25%
The Journal of Nuclear Medicine again ranks among the top 5 medical imaging journals in the world.

Nuclear medicine PSMA-targeted study offers new options for cancer theranostics worldwide
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) describes a new class of radiopharmaceuticals, named radiohybrids (rh), that offer a fresh perspective on cancer imaging and radioligand therapy (theranostics).

Nuclear medicine imaging monitors effectiveness of therapy for melanoma patients
Nuclear medicine imaging with PET/CT can monitor the effectiveness of immunotherapy treatment for metastatic melanoma and predict outcome.

Prostate cancer radiotherapy more precisely targeted with nuclear medicine imaging
A nuclear medicine imaging procedure can pinpoint prostate cancer with superior accuracy, allowing more precisely targeted treatment, according to new research featured in the November 2018 issue of The Journal of Nuclear Medicine.

New nuclear medicine tracer will help study the aging brain
A new PET imaging radiotracer could help researchers understand neurodegenerative disease and the aging brain.

New nuclear medicine imaging method shows strong potential for cancer imaging
A new nuclear medicine imaging method could help diagnose widespread tumors, such as breast, colon, pancreas, lung and head and neck cancer better than current methods, with less inconvenience to patients and with equal or improved accuracy.

New nuclear medicine technique could help tackle brain disease
A new molecular imaging method can monitor the success of gene therapy in all areas of the brain, potentially allowing physicians to more effectively tackle brain conditions such as Parkinson's disease, Alzheimer's disease and multiple sclerosis.

Read More: Nuclear Medicine News and Nuclear Medicine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to